|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||35.17 - 37.21|
|52-week range||13.19 - 37.21|
|Beta (5Y monthly)||0.60|
|PE ratio (TTM)||N/A|
|Earnings date||28 Mar 2023 - 03 Apr 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||36.86|
WILMINGTON, Del. & NEW YORK, January 26, 2023--Phreesia, a leader in patient intake, outreach and activation, along with the Ad Council, a nonprofit organization at the forefront of driving change through social impact marketing, have collaborated to bring three public health campaigns directly to patients and caregivers. Initial results show the campaigns are helping to raise awareness about critical health issues and encouraging important conversations between patients, caregivers and healthca
WILMINGTON, Del., January 20, 2023--Phreesia, a leader in patient intake, outreach and activation, is pleased to announce that for the second year in a row, the healthcare marketing industry trade publication Medical Marketing and Media (MM+M) has named Phreesia Life Sciences to its list of Best Places to Work 2022.
Phreesia (PHR) delivered earnings and revenue surprises of 13.64% and 2.73%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?